Overview

Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

To facilitate the clinical testing of seviteronel and dexamethasone (SEVI-D) in combination with docetaxel in androgen receptor (AR) positive triple-negative breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

St Vincent's Hospital, Sydney

Treatments:

Dexamethasone
Docetaxel
Seviteronel